1. Introduction {#sec1}
===============

Gastro-intestinal nematodes are very common in cattle and can cause pathology which impairs the health and welfare of infected animals, therefore resulting in decreased production. The use of broad spectrum anthelmintic drugs has been the backbone of worm management for nearly 40 years. This continual use has led to the selection of populations of drug-resistant worms worldwide. The high prevalence of anthelmintic resistance and even multidrug resistance in sheep is redefining how anthelmintics are used in parasite control programs. Anthelmintic resistance to both benzimidazole and macrocyclic lactone compounds has now also been reported in cattle ([@bib39]). For the macrocyclic lactone compounds, anthelmintic resistance in cattle has mainly been reported in the dose-limiting nematode *Cooperia* spp. ([@bib37; @bib9; @bib20; @bib17; @bib18; @bib19; @bib31; @bib2; @bib26]) and to a far lesser extent in *Ostertagia ostertagi* ([@bib11; @bib1]). Species belonging to the genus *Cooperia* are considered to be of less pathogenic significance than *Ostertagia*, although the negative effect of *Cooperiapunctata* on cattle productivity has been demonstrated in the US ([@bib38]).

The ostensibly lower rate of anthelmintic resistance detection in cattle might in part be due to the difficulty in diagnosis, as faecal egg counts tend to be less reflective of the adult worm burden in cattle compared to sheep. As such, the detection of anthelmintic resistance based on faecal egg counts is prone to more uncertainty in cattle. Some recommendations to minimise diagnostic uncertainty include the use of arithmetic means over geometric means to calculate anthelmintic efficacy ([@bib15]), the use of individual based group means with pre- and post-treatment individual faecal egg counts ([@bib5]), and the preferred use of diagnostic methods with higher analytic sensitivity to minimise inaccuracies in populations with low baseline faecal egg count ([@bib27]). It is also important to obtain an adequate sample size, although the number of animals with an adequate infection for enrolment can be limited under field conditions. To account for the problems associated with smaller sample sizes, the use of parametric methods such as Markov chain Monte Carlo within a Bayesian framework have been advocated in equine studies for all group sizes smaller than 50 animals, in order to avoid erroneous inference about the true efficacy of anthelmintics in the field ([@bib12]). Bayesian methods have also more recently been advocated by other authors ([@bib16; @bib40]). Non-parametric bootstrapping has also been considered as a potential analysis method ([@bib42]), but it has been found to be inappropriate for smaller sample sizes ([@bib12]), and does not produce correct results with observed reductions of 100% ([@bib12; @bib16; @bib40]).

In addition to the method of statistical analysis, the interpretation of the efficacy results and the definition of anthelmintic resistance have been debated. The current WAAVP (World Association for the Advancement of Veterinary Parasitology) guidelines ([@bib7]) state that anthelmintic resistance is present when the efficacy is below 95% and when the lower 95% confidence limit is below 90%, and that anthelmintic resistance is suspected if only one of the two criteria applies. More recently, there have been recommendations to include the upper 95% confidence limit in the assessment of the true resistance status ([@bib30]), which distinguishes between the two situations where anthelmintic resistance is possible but not certain, and where anthelmintic resistance has been confirmed.

The objective of the current study was to obtain more information on anthelmintic resistance in cattle in Europe. The efficacy of injectable formulations of ivermectin and moxidectin was evaluated in naturally infected cattle in four major cattle markets across Europe.

2. Materials and methods {#sec2}
========================

2.1. Study design {#sec2.1}
-----------------

This study was designed as a multi-site field efficacy study in Germany, France, the UK and Italy. The anthelmintic efficacy was assessed in cattle naturally infected with gastro-intestinal nematodes. The study farms were selected based on the previous use of macrocyclic lactones as the backbone for parasite management. On each farm, all animals grazed the same pasture before and throughout the 14 day evaluation period. The study used a randomised complete block design for each farm, with the individual animal as the experimental unit. In accordance with current guidelines, a faecal egg count was used to select animals for treatment. In order to ensure an adequate number of animals with a positive faecal egg count for randomisation (a target of 20 animals), individual faecal samples from 20 to 50 animals were screened at each farm prior to treatment.

On each farm, animals were paired into blocks by descending pre-treatment faecal egg count. Within each block of two, the animals were randomly allocated to one of the two treatment groups. On Day 0, the weight of the allocated animals was determined using a girth tape. Animals were treated with injectable formulations of either ivermectin (Ivomec^®^ Merial) or moxidectin (Cydectin 1%^®^ Zoetis), both at 0.2 mg/kg bodyweight. On Day 14 (±2 days), individual faecal egg counts were performed for all animals selected for treatment. Faecal egg counts were performed using a modified McMaster technique, with a sensitivity of 12.5 eggs per gram of faeces in all countries except France (detection limit: 15 eggs per gram of faeces). Coprocultures were performed for larval identification ([@bib41]), based on a single bulk sample (before treatment) or a bulk sample per treatment group (after treatment). Laboratory personnel involved in the faecal egg count and/or the larval identification were blinded to the allocation of animals to treatment. The *in vivo* procedures occurred after ethical review and according to state, national, or international regulations.

2.2. Statistical analysis {#sec2.2}
-------------------------

At each farm, the pre-treatment and post-treatment arithmetic mean faecal egg counts were used to calculate the efficacy for each of the treatment groups using the following formula:$$\text{\%}\ \text{reduction} = 100 \times \frac{\left( \text{pre} - \text{treatment}\ \text{count} \right) - \left( \text{post} - \text{treatment}\ \text{count} \right)}{\text{pre} - \text{treatment}\ \text{count}}$$

Where possible, the percentage reduction per nematode species (*Ostertagia* and *Cooperia*) was calculated. A bootstrap analysis approach based on [@bib42] was used to estimate the arithmetic mean faecal egg count reduction per treatment and the 95% confidence intervals. For each dataset, new values for the pre- and post-treatment counts were sampled with replacement from the observed counts, and the bootstrapped efficacy was calculated as described above. This was repeated 1000 times and the 95% confidence intervals taken as the 2.5 and 97.5 percentiles of the resulting distribution of bootstrapped efficacies. All statistical analyses were performed using R ([@bib34]).

2.3. Interpretation of results {#sec2.3}
------------------------------

The anthelmintic resistance status was interpreted using the method described by [@bib30], which is based on the WAAVP guidelines on anthelmintic resistance ([@bib7]) but also considers the upper 95% confidence limit as well as the lower 95% confidence limit and the percentage reduction. The treatment was classified as either efficacious, having confirmed anthelmintic resistance, or being inconclusive based on the following criteria:•Efficacious: percentage reduction and upper 95% confidence limit above 95% and lower 95% confidence limit above 90%.•Confirmed anthelmintic resistance: percentage reduction and upper 95% confidence limit below 95% and lower 95% confidence limit below 90%.•Inconclusive: neither of the above criteria fulfilled.

Datasets with 100% observed efficacy were tentatively classified as efficacious in accordance with these criteria, however these classifications should not be considered as definitive because the lower 95% confidence intervals produced using non-parametric bootstrapping for these datasets cannot be relied upon ([@bib12; @bib16; @bib40]).

2.4. Comparison of the sampling assumptions and analytical methods {#sec2.4}
------------------------------------------------------------------

In order to explore the statistical consequences and implications of the standard protocol followed for this study, data from the 80 trials were re-analysed under three sampling assumptions including the *screened* data as described above. To generate the second group of datasets, the entire pre-treatment data were considered. This included data from animals that were not enrolled in the treatment groups due to a low or negative faecal egg count from this sample (*unscreened* data). The motivation was to correct for regression to the mean, induced by using the same faecal egg count sample as both the screening and pre-treatment sample, which would be expected to introduce a bias in the estimated efficacy calculation. The third procedure involved extending the first procedure to utilise the pre-treatment data from both treatment groups in order to reduce the uncertainty in the estimated efficacy (*grouped* data).

All three datasets from each of the 80 trials were analysed using two statistical methods: a modified non-parametric bootstrap method, and an Markov chain Monte Carlo method. The latter was modified from [@bib12] to allow an individual animal efficacy fitted to those animals for which a post-treatment faecal egg count was observed. This approach explicitly controls for several levels of within individual extra-Poisson variance, as described by [@bib13]. These statistical analyses were done in R ([@bib34]), with Markov chain Monte Carlo results obtained using the bayescount package ([@bib14]). Full details of these methods are given in the [supplementary](#appsec1){ref-type="sec"} data file.

3. Results {#sec3}
==========

A total of 40 farms and 753 animals were included in this study: 12 farms in Germany with 235 animals, 10 farms each in Italy (179 animals) and the UK (197 animals) and 8 farms (142 animals) in France. In addition to an overview of the efficacy results by country, the number of animals in each country is provided in [Table 1](#tbl1){ref-type="table"}. The number of animals enrolled in each treatment group varied between seven and ten (see [Tables 2--5](#tbl2 tbl3 tbl4 tbl5){ref-type="table"}). Of the 80 treatment groups in the study, 54 groups had ten animals, 14 groups had nine animals, 6 groups had eight animals, 5 groups had seven animals and 1 group had six animals included in the analysis. For some animals, a faecal sample could not be collected after treatment.

The bulk coprocultures before and after treatment provide further insight into which nematode species are potentially involved in the decreased efficacy or confirmed anthelmintic resistance. The data are presented per farm in [Tables 2--5](#tbl2 tbl3 tbl4 tbl5){ref-type="table"} In [Table 6](#tbl6){ref-type="table"}, an overview of the efficacy against *Cooperia* and *Ostertagia*, based on the reduction in mean faecal egg counts and the larval identification before and after treatment is provided.

3.1. Germany {#sec3.1}
------------

The results in Germany are summarised in [Table 2](#tbl2){ref-type="table"}. The study was conducted from August 2011 to September 2012 on 12 dairy farms in Northern Germany in the regions of Lower Saxony (GE01-03, GE05-09, GE11), Schleswig--Holstein (GE04 and GE10) and Brandenburg (GE12).

The baseline faecal egg count in Germany was medium to high, with an arithmetic mean faecal egg count between 60 and 836 eggs per gram of faeces, and an individual faecal egg count ranging from 25 to 5587.5 eggs per gram of faeces. Moxidectin was considered to be efficacious on four farms (GE02; GE05; GE10 and GE12). Anthelmintic resistance was confirmed on 1 farm (GE01) and seven cases were found to be inconclusive. In 5 of these cases, the species-specific efficacy calculation ([Table 6](#tbl6){ref-type="table"}) indicated that the efficacy was below 95% for *Cooperia* and *Ostertagia* (GE07, GE11) or for *Cooperia* only (GE03, GE04, GE06). Ivermectin was considered to be efficacious on two farms (GE03 and GE04), of which the latter was associated with an observed reduction of 100%. Confirmed anthelmintic resistance was identified on the same farm as for moxidectin (GE01). Nine cases were found to be inconclusive. In 5 of these cases, the species-specific efficacy calculation ([Table 6](#tbl6){ref-type="table"}) indicated that the efficacy was below 95% for *Cooperia* and *Ostertagia* (GE07, GE08, GE12) or for *Cooperia* only (GE11, GE09). Before treatment, *O. ostertagi* was identified in all farms and *Cooperia* spp. in all but one of the farms. Small percentages of *Trichostongylus* spp. were also identified (data not shown). Overall, *Cooperia* spp. was the most prevalent nematode after treatment. Nevertheless, *O. ostertagi* was identified in eight of the ten moxidectin and in nine of the ten ivermectin treatment groups from which larvae could be retrieved after treatment.

3.2. Italy {#sec3.2}
----------

The results in Italy are summarised in [Table 3](#tbl3){ref-type="table"}. The study was conducted in beef cattle farms from October to December 2012 in the northern part of Italy (Veneto region: IT01-05) and from December 2011 to February 2012 in the southern part of Italy (Apulia region: IT06-10).

The baseline faecal egg count in Italy was low to medium, with an arithmetic mean faecal egg count between 35 and 131 eggs per gram of faeces, and an individual faecal egg count ranging from 25 to 450 eggs per gram of faeces. Moxidectin was considered to be efficacious on nine farms, all of which were associated with a 100% observed reduction. On one farm (IT05) in northern Italy the results were found to be inconclusive. Ivermectin was found to be efficacious on seven farms (two farms in northern Italy and five in southern Italy), all of which were associated with a 100% observed reduction. The results of the remaining three farms (IT01, IT02 and IT03) were inconclusive.

Before treatment *Haemonchus* spp. was the only worm identified on all farms, with one exception (IT01: which also had *Cooperia* and *Oesophagostomum*; data not shown). The only nematode identified after treatment was *Haemonchus* spp.

3.3. United Kingdom {#sec3.3}
-------------------

The results in the UK are summarised in [Table 4](#tbl4){ref-type="table"}. The study was conducted on five dairy farms (UK06-10) in Northumberland from July to September 2011, and five dairy farms (UK02 and UK11-14) in the region of West Sussex from August 2011 to October 2012.

The baseline faecal egg count in the UK was medium to high, with an arithmetic mean faecal egg count between 95 and 722 eggs per gram of faeces, and an individual faecal egg count ranging from 37.5 to 3075 eggs per gram of faeces. It is interesting to note that on farms UK02 and UK14, all treated animals were excreting eggs by 14 days after ivermectin and moxidectin treatment. Moxidectin was considered to be efficacious on four farms (UK09, UK10, UK11 and UK13), of which one farm (UK09) was associated with a 100% observed reduction. Anthelmintic resistance was confirmed on one farm (UK14) and five cases were found to be inconclusive. In 4 of these cases, the species-specific efficacy calculation ([Table 6](#tbl6){ref-type="table"}) indicated that the efficacy was below 95% for *Cooperia* and *Ostertagia* (UK02) or for *Cooperia* only (UK07, UK08, UK12). Ivermectin was considered to be efficacious on three farms (UK07, UK09 and UK10), of which 1 farm (UK09) was associated with a 100% observed reduction. Confirmed anthelmintic resistance was identified on three farms (UK02, UK12 and UK14), and the results on four farms were inconclusive. In 3 of these cases, the species-specific efficacy calculation ([Table 6](#tbl6){ref-type="table"}) indicated that the efficacy was below 95% for *Cooperia* and *Ostertagia* (UK11, UK13) or for *Cooperia* only (UK08).

Before treatment, coprocultures were successful for nine out of ten farms and both *Cooperia* spp. and *O. ostertagi* were identified. The most prevalent nematode after treatment was *Cooperia* spp. although *O. ostertagi* was also identified on seven farms after moxidectin treatment (10--94% of the larvae) and on five farms after ivermectin treatment (6--100% of the larvae). On one farm (UK06), 94% of the larvae after moxidectin treatment and 100% of the larvae after ivermectin treatment were identified as *O. ostertagi*.

3.4. France {#sec3.4}
-----------

The results of the eight dairy farms in France are summarised in [Table 5](#tbl5){ref-type="table"}. The study was conducted from November 2011 to September 2012, in the region of Nantes.

The baseline faecal egg count in France was low to medium, with an arithmetic mean faecal egg count between 40 and 216 eggs per gram of faeces, and an individual faecal egg count ranging from 15 to 1125 eggs per gram of faeces. Moxidectin was considered as efficacious on three farms (FR01, FR05 and FR08), all of which were associated with a 100% observed reduction. Confirmed anthelmintic resistance was observed on three farms (FR06, FR09 and FR12), and on two farms the results were inconclusive. Ivermectin was efficacious on four farms (FR01, FR08, FR09 and FR11), of which three farms (FR01, FR08 and FR11) were associated with a 100% observed reduction. Anthelmintic resistance was confirmed for ivermectin on one farm (FR12), and on three farms the results were inconclusive. The species-specific efficacy calculation ([Table 6](#tbl6){ref-type="table"}) indicated that the efficacy was below 95% for *Cooperia* only (FR06).

Before treatment, coprocultures were successful for seven out of eight farms: *Cooperia* spp. was identified on seven farms and *O. ostertagi* was identified on five farms. The most prevalent nematodes after treatment were *Cooperia* spp. In France, only a small percentage of *O. ostertagi* larvae were identified after ivermectin treatment on FR09. The coproculture of FR02 and FR11 did not yield any larvae.

3.5. Comparison of the sampling assumptions and analytical methods {#sec3.5}
------------------------------------------------------------------

There was no significant difference between the observed efficacy from the 80 trials as calculated from the *grouped* and *unscreened* datasets, although the additional pre-treatment data reduced the uncertainty in the true reduction. This was reflected in smaller 95% confidence intervals and therefore fewer datasets classified as inconclusive for the *grouped* data compared to the *unscreened* data (one fewer for Markov chain Monte Carlo and five fewer for the bootstrap method). However, the *screened* datasets significantly over-estimated the efficacy (compared to the *grouped* datasets) by an average of 2.4% over the 80 trials, and for the bootstrap method in particular, were also associated with a tendency to classify trials as efficacious or inconclusive rather than inconclusive or confirmed anthelmintic resistance. Each of the 25 trials with 100% observed reductions were classified as inconclusive by the Markov chain Monte Carlo method using *screened*, *unscreened* and *grouped* datasets, indicating that the non-parametric bootstrap classification of efficacious produced by the non-parametric bootstrap is not reliable for these datasets. Based on the *grouped* data from the remaining 55 trials with observed reductions of less than 100%, 19 were classified as confirmed anthelmintic resistance by both Markov chain Monte Carlo and bootstrap, 26 as inconclusive by both methods, 3 as inconclusive by bootstrap but confirmed anthelmintic resistance by Markov chain Monte Carlo, and 7 as efficacious by bootstrap but inconclusive by Markov chain Monte Carlo. Full results of the comparison between the analytical methods are given in the [Supplementary](#appsec1){ref-type="sec"} data file.

4. Discussion {#sec4}
=============

This study provides an insight into the current state of efficacy of injectable macrocyclic lactone anthelmintics on commercial cattle farms in Germany, Italy, France and the UK. The efficacy in this study was calculated based on arithmetic group means before and after treatment, and was evaluated taking both the lower and upper 95% confidence limit into account. This allowed the definition of three categories: efficacious, confirmed anthelmintic resistance or inconclusive ([@bib30]). As the criteria are based on upper and lower 95% confidence intervals as well as a calculated percent reduction, the conclusions are dependent on accurate estimates obtained using an appropriate statistical method. In the main text of this paper, standard non-parametric bootstrap methods have been used to estimate the lower and upper 95% confidence intervals. Based on these estimates and on the interpretation as suggested by [@bib30], a considerable number of groups were classified as inconclusive. Without consideration of the upper 95% confidence interval these groups would be incorrectly classified as either suspected or confirmed anthelmintic resistance.

Using the Markov chain Monte Carlo method presented in the [supplementary](#appsec1){ref-type="sec"} file to generate 95% confidence intervals, an even larger number of groups were classified as inconclusive. This illustrates the difficulties in accurately evaluating anthelmintic efficacy based on faecal egg counts in cattle, especially in bovine populations with a low baseline faecal egg excretion. It is also important to note that non-parametric bootstrapping is unable to deal appropriately with an observed reduction of 100% ([@bib12; @bib16; @bib40]) and can therefore yield incorrect conclusions in these situations. It is concerning that no groups were classified as efficacious by the Markov chain Monte Carlo method, which suggests that larger sample sizes are required to confidently determine situations where the true efficacy is greater than 95%. Nevertheless, a number of farms with confirmed anthelmintic resistance were consistently identified, as discussed below.

The selection of the farms in this study was based on their previous use of macrocyclic lactone compounds which may have led to an increased selection for the development of anthelmintic resistance. However, the main emphasis of this study was not to estimate the true prevalence of anthelmintic resistance on cattle farms in the respective geographical regions. Instead, this study intended to evaluate the current efficacy situation on farms that were selected to be representative of the relevant market, and therefore regularly use macrocyclic lactones. The threshold for adequate efficacy was set at 95% in this study, in line with the recommendations for macrocyclic lactones ([@bib7; @bib8]). Nevertheless, this general threshold does not take potential differences in regional management practices or climate factors into account, and might therefore underestimate the anthelmintic resistance status in regions with high baseline efficacy. In Italy for example ([@bib22; @bib35]), high efficacy of anthelmintics are commonly reported in sheep, in contrast to other EU countries, suggesting a higher threshold for efficacy might be required. It was however preferred to use a common threshold for all countries included, for consistency in this multi-centre study. Specifically for Italy, this general threshold is not believed to have resulted in an underestimation of the resistance status, given the low number of cattle excreting eggs after treatment.

The treatment efficacy in our study was evaluated based on faecal egg count rather than worm counts, because the study animals were owned by the farmers. There are a number of limitations associated with anthelmintic efficacy evaluation based on faecal egg counts, which have been discussed before ([@bib15; @bib12; @bib27; @bib28]). In the present study, a diagnostic method with a low detection limit was used to minimise the problems caused by populations with a low to medium baseline faecal egg count. However, even with this detection limit, identifying animals with an adequate infection proved challenging, reflecting the low baseline faecal egg count commonly observed in cattle in Europe. As a result, up to 50 animals had to be screened on each farm prior to treatment in order to reach the target number of 10 animals in the majority of the treatment groups (88% of the treatment groups had 9 or 10 animals). The sample group sizes are in line with previous studies in Europe ([@bib11; @bib1]), and with the WAAVP guidance on anthelmintic resistance evaluation ([@bib7]). However, larger group sizes are known to increase the accuracy of the efficacy evaluation, which has been noted by several authors using more sophisticated methods of analysis than those recommended in the current WAAVP guidelines ([@bib23; @bib12; @bib28]).

Moxidectin was found to be efficacious on 20 and ivermectin on 16 out of 40 farms (including the datasets with 100% reduction). In all countries except Italy, a high number of farms with decreased efficacy were observed (ivermectin; n = 24 and moxidectin; n = 20). Some of these cases with decreased efficacy were listed as inconclusive, as it is not possible to classify them as fully effective or as confirmed anthelmintic resistance based on the available faecal egg count data. Looking however into the efficacy calculation for each parasite, it is clear that at least part of those inconclusive cases concern a species-specific efficacy below the efficacy threshold for macrocyclic lactones. The adequate or near to adequate efficacy against one nematode species sometimes masks the clear resistance against the other species, and might lead to an underestimation of species-specific resistance cases. Despite this observation, confirmed anthelmintic resistance was found in 5 farms (12.5%) each for moxidectin and ivermectin. In total, 7 farms (17.5%) had confirmed anthelmintic resistance in at least one of the treatment groups, and on 3 farms (7.5%) confirmed anthelmintic resistance was identified in both groups (GE01, UK14 and FR12), confirming previous observations that ivermectin and moxidectin share some degree of cross-resistance, but not complete cross-resistance ([@bib33]). It is currently thought that both drugs act via irreversibly opening of the GABA and glutamate gate-chloride channels leading to a flaccid paralysis. However, it is unclear which resistance mechanisms apply and it has been discussed whether drug-specific differences in the involved mechanisms (e.g concerning transmembrane P-glycoproteins), may contribute to different drug efficacy phenotypes ([@bib4]).

In Italy, decreased efficacy for ivermectin (associated with the nematode *Haemonchus* spp.) was identified on three farms, although the results were inconclusive. In cattle, anthelmintic resistance against *Haemonchus* has previously been reported in the US ([@bib20]) and in Brazil ([@bib37]).

Anthelmintic resistance was confirmed in France for both ivermectin and moxidectin on 1 and 3 farms respectively, but this was mainly associated with the dose-limiting nematode species *Cooperia* spp. In contrast, anthelmintic resistance in the UK and Germany was due not only to the dose-limiting nematode species, but also to the more pathogenic abomasal nematode *O. ostertagi,* which was also identified in cases of confirmed anthelmintic resistance. Calculating the species-specific efficacy, confirms that reduced efficacy is mainly observed in *Cooperia*, although in 25% of the farms for which this calculation could be done, the efficacy of both ivermectin and moxidectin against *Ostertagia* was below 95% (all in the UK and Germany). This is in contrast to previous efficacy evaluations of macrocyclic lactone compounds under European field conditions, in which decreased efficacy was mostly associated with *Cooperia* ([@bib11; @bib2]). In a recent study in Sweden, *O. ostertagi* was identified on 15% of farms after ivermectin or doramectin treatment with topical formulations ([@bib1]).

The suppression of the egg excretion by *Cooperia* spp. worms following moxidectin treatment has been described ([@bib9; @bib10; @bib29]), potentially leading to an overestimation of the moxidectin efficacy against *Cooperia* spp. based on faecal examination. However, where *Cooperia* spp. larvae were identified after treatment with ivermectin on our study farms, they were also observed on the same farm (and in similar proportions) after treatment with moxidectin. The comparable proportions after treatment seem to suggest that on farms with decreased efficacy of ivermectin against *Cooperia*, the efficacy of moxidectin was not overestimated due to a suppressed egg excretion.

The results of the current study indicate that anthelmintic resistance is an increasing reality in three major cattle rearing countries in Europe, and that this concerns not only the dose-limiting species but also *O. ostertagi*. This should incite the different stakeholders, farmers as well as vets and industry, to work towards what has been referred to as a paradigm shift in parasite control ([@bib32]). The key message is that management advice should be based on a sound understanding of the parasite epidemiology and farm management, past and present, and that the requirement for and appropriate timing of treatment should be established based on faecal examinations. In the present study, screening of up to 50 animals was needed to identify a sufficient number of animals with an adequate infection prior to treatment. This indicates that not all animals need treatment at the same time and that an approach with targeted treatments could be considered. Different approaches, including Targeted Selective Treatments programs, to decrease the selection pressure for the development of anthelmintic resistance in ruminants, have previously been discussed ([@bib24; @bib6]). The use of combination anthelmintics has also been advocated, in order to increase the farm treatment efficacy and consequently prevent the introduction of resistance genes into the worm population ([@bib36]) and also to protect any new anthelmintic compound ([@bib3; @bib21; @bib24]). Nevertheless, any new combination anthelmintic must be used in a sustainable manner ([@bib25]).
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The following is the supplementary data related to this article:
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###### 

The number of farms with adequate efficacy (EFF), confirmed anthelmintic resistance (CAR) or inconclusive (INC) for ivermectin (IVM) and moxidectin (MOX), and the number of farms with CAR for both IVM and MOX. The number of farms (N farms), and the number of animals per treatment group (N animals) are provided per country.

  Country   N farms   MOX   IVM   CAR for IVM and MOX                            
  --------- --------- ----- ----- --------------------- ---- ----- ---- --- ---- ----
  Germany   12        118   4     1                     7    117   2    1   9    2
  Italy     10        88    9     0                     1    91    7    0   3    0
  UK        10        99    4     1                     5    98    3    3   4    4
  France    8         71    3     3                     2    71    4    1   3    4
  Total     40        376   20    5                     15   377   16   5   19   10

###### 

The arithmetic mean (AM), minimum (MIN) and maximum (MAX) faecal egg counts before (pre) and after (post) treatment for each treatment group on the 12 farms (GE01-12) in Germany. The number of animals in each treatment group (n) and the number of animals with a positive faecal egg count after treatment (n pos) are provided, along with the % larvae before and after treatment (Oo = *Ostertagia ostertagi* and C = *Cooperia* spp). The percentage (%) efficacy is provided calculated based on the arithmetic group mean, along with the lower (L95) and upper (U95) 95% confidence limits. The anthelmintic resistance status (Status) is provided as EFF (efficacious), confirmed anthelmintic resistance (CAR) or Inconclusive (INC).

  Farm   Treatment   Pre   Post   Efficacy   Larvae pre   Larvae post                                                                      
  ------ ----------- ----- ------ ---------- ------------ ------------- ---- ------ ------- ------- ------- ------- ----- ----- ---- ----- -----
  GE01   MOX         10    260    75         550          8             58   0      187.5   76.8    56.9    90.4    CAR   44    56   3     97
  IVM    10          258   62.5   475        9            55            0    150    78.3    63.3    88.4    CAR     3     97               
  GE02   MOX         10    75     25         187.5        2             3    0      12.5    96.5    91.3    100.0   EFF   100   0    100   0
  IVM    10          75    37.5   175        2            4             0    25     94.9    86.8    100.0   INC     90    10               
  GE03   MOX         10    133    12.5       625          3             9    0      62.5    92.0    75.0    100.0   INC   77    22   0     100
  IVM    10          109   12.5   475        1            1             0    12.5   98.7    94.6    100.0   EFF     NL                     
  GE04   MOX         10    89     25         325          1             4    0      37.5    95.5    82.4    100.0   INC   40    60   0     100
  IVM    10          129   25     587.5      0            0             0    0      100.0   100.0   100.0   EFF     0     100              
  GE05   MOX         10    836    62.5       5587.5       6             15   0      37.5    97.3    91.1    99.5    EFF   20    80   2     95
  IVM    10          465   37.5   2212.5     5            18            0    75     95.2    85.7    99.1    INC     2     98               
  GE06   MOX         10    106    12.5       387.5        5             23   0      125     77.2    37.3    96.7    INC   21    79   5     95
  IVM    10          96    12.5   262.5      2            4             0    25     95.7    87.3    100.0   INC     5     95               
  GE07   MOX         8     78     12.5       225          4             8    0      25      89.0    76.5    97.4    INC   4     95   6     94
  IVM    7           75    25     200        3            7             0    25     89.9    73.9    98.4    INC     30    67               
  GE08   MOX         10    69     25         150          3             4    0      12.5    94.4    88.0    98.6    INC   91    6    NL    
  IVM    10          66    12.5   137.5      2            20            0    175    69.6    8.3     100.0   INC     24    76               
  GE09   MOX         10    64     12.5       212.5        4             9    0      25      85.0    64.7    97.3    INC   43    57   NL    
  IVM    10          60    12.5   162.5      2            3             0    12.5   95.7    88.6    100.0   INC     10    90               
  GE10   MOX         10    101    37.5       237.5        2             3    0      12.5    97.5    93.8    100.0   EFF   31    69   13    87
  IVM    10          74    12.5   175        3            5             0    25     92.8    83.3    98.6    INC     NL                     
  GE11   MOX         10    103    50         175          4             13   0      50      87.5    75.0    97.1    INC   44    56   29    71
  IVM    10          114   50     250        3            5             0    25     95.5    89.6    100.0   INC     9     91               
  GE12   MOX         10    86     37.5       200          3             4    0      12.5    95.4    90.0    99.2    EFF   35    64   13    88
  IVM    10          129   37.5   650        5            66            0    450    36.6    0.00    95.3    INC     20    80               

NL = no larvae were found in the coproculture. MOX = moxidectin injectable. IVM = ivermectin injectable.

###### 

The arithmetic mean (AM), minimum (MIN) and maximum (MAX) faecal egg counts before (pre) and after (post) treatment for each treatment group on the 10 farms (IT01-10) in Italy. The number of animals in each treatment group (n) and the number of animals with a positive faecal egg count after treatment (n pos) are provided, along with the % larvae before and after treatment (Hae = *Haemonchus* spp. and C = *Cooperia* spp). The percentage (%) efficacy calculated based on the arithmetic group mean is provided, along with the lower (L95) and upper (U95) 95% confidence limits. The anthelmintic resistance status (Status) is provided as EFF (efficacious), confirmed anthelmintic resistance (CAR) or Inconclusive (INC).

  Farm   Treatment   Pre   Post   Efficacy   Larvae pre   Larvae post                                                                                                                                
  ------ ----------- ----- ------ ---------- ------------ ------------- --- ----- ------ ------- ------- ------- ----- -------------------------------------- -------------------------------------- ----
  IT01   MOX         10    63     25         125          0             0   0     0      100     100.0   100.0   EFF   78[a](#tbl3fna){ref-type="table-fn"}   18[a](#tbl3fna){ref-type="table-fn"}   
  IVM    9           97    50     400        3            19            0   100   77.1   36.3    100.0   INC     100   0                                                                             
  IT02   MOX         9     111    25         400          0             0   0     0      100     100.0   100.0   EFF   100                                    0                                      
  IVM    9           131   25     450        2            6             0   25    95.4   87.1    100.0   INC     100   0                                                                             
  IT03   MOX         6     42     25         75           0             0   0     0      100     100.0   100.0   EFF   100                                    0                                      
  IVM    8           41    25     100        1            6             0   50    84.6   50.0    100.0   INC     100   0                                                                             
  IT04   MOX         6     42     25         75           0             0   0     0      100     100.0   100.0   EFF   100                                    0                                      ND
  IVM    8           50    25     200        0            0             0   0     100    100.0   100.0   EFF                                                                                         
  IT05   MOX         7     64     25         225          1             4   0     25     93.4    71.4    100.0   INC   100                                    0                                      NL
  IVM    7           39    25     100        0            0             0   0     100    100.0   100.0   EFF                                                                                         
  IT06   MOX         10    38     25         62.5         0             0   0     0      100     100.0   100.0   EFF   100                                    0                                      ND
  IVM    10          40    25     112.5      0            0             0   0     100    100.0   100.0   EFF                                                                                         
  IT07   MOX         10    49     25         125          0             0   0     0      100     100.0   100.0   EFF   100                                    0                                      ND
  IVM    10          46    25     100        0            0             0   0     100    100.0   100.0   EFF                                                                                         
  IT08   MOX         10    46     25         87.5         0             0   0     0      100     100.0   100.0   EFF   100                                    0                                      ND
  IVM    10          48    25     87.5       0            0             0   0     100    100.0   100.0   EFF                                                                                         
  IT09   MOX         10    38     25         75           0             0   0     0      100     100.0   100.0   EFF   100                                    0                                      ND
  IVM    10          35    25     50         0            0             0   0     100    100.0   100.0   EFF                                                                                         
  IT10   MOX         10    46     25         137.5        0             0   0     0      100     100.0   100.0   EFF   100                                    0                                      ND
  IVM    10          45    25     112.5      0            0             0   0     100    100.0   100.0   EFF                                                                                         

ND = for those groups with high efficacy no copro-culture was performed. NL = no larvae were found in the coproculture.

MOX = moxidectin injectable. IVM = ivermectin injectable.

On IT01, *Oesophagostomum* (4%) was identified as well pre-treatment.

###### 

The arithmetic mean (AM), minimum (MIN) and maximum (MAX) faecal egg counts before (pre) and after (post) treatment for each treatment group on the 10 farms (UK02 and UK06-14) in the UK. The number of animals in each treatment group (n) and the number of animals with a positive faecal egg count after treatment (n pos) are provided, along with the % larvae before and after treatment (Oo = *Ostertagia ostertagi* and C = *Cooperia* spp). The percentage (%) efficacy calculated based on the arithmetic group mean is provided, along with the lower (L95) and upper (U95) 95% confidence limits. The anthelmintic resistance status (Status) is provided as EFF (efficacious), confirmed anthelmintic resistance (CAR) or Inconclusive (INC).

  Farm   Treatment   Pre   Post    Efficacy   Larvae pre   Larvae post                                                                        
  ------ ----------- ----- ------- ---------- ------------ ------------- ------ ------- ------- ------- ------- ------- ----- ----- ---- ---- -----
  UK02   MOX         10    353     37.5       800          10            35     12.5    125     89.8    80.8    95.3    INC   10    47   17   68
  IVM    10          320   12.5    862.5      10           61            12.5   237.5   79.3    55.6    92.5    CAR     0     99              
  UK06   MOX         10    243     162.5      412.5        6             21     0       62.5    91.2    84.5    96.9    INC   NL    94   6    
  IVM    10          234   150     350        6            13            0      50      94.6    90.6    98.0    INC     100   0               
  UK07   MOX         10    254     87.5       762.5        2             9      0       75      96.4    89.6    100.0   INC   41    52   0    100
  IVM    10          223   75      400        2            3             0      12.5    98.8    97.0    100.0   EFF     0     90              
  UK08   MOX         10    170     62.5       625          7             14     0       25      91.2    83.9    96.0    INC   57    40   16   84
  IVM    10          126   62.5    337.5      5            29            0      187.5   76.8    41.3    96.3    INC     6     94              
  UK09   MOX         10    95      50         175          0             0      0       0       100.0   100.0   100.0   EFF   69    17   NL   
  IVM    10          105   50      250        0            0             0      0       100.0   100.0   100.0   EFF                           
  UK10   MOX         10    216     75         437.5        2             3      0       12.5    98.8    97.1    100.0   EFF   21    55   0    100
  IVM    10          303   137.5   937.5      1            1             0      12.5    99.6    98.6    100.0   EFF     0     100             
  UK11   MOX         9     722     212.5      3075         4             18     0       50      97.1    92.1    99.5    EFF   21    78   32   68
  IVM    9           546   187.5   2162.5     6            63            0      175     86.8    67.4    97.2    INC     29    70              
  UK12   MOX         10    391     125        925          6             21     0       137.5   94.5    86.2    98.8    INC   56    44   10   90
  IVM    10          388   125     687.5      7            56            0      175     85.0    72.7    95.0    CAR     18    82              
  UK13   MOX         10    299     150        737.5        5             11     0       62.5    96.2    91.3    99.1    EFF   26    74   21   79
  IVM    9           351   137.5   1137.5     5            63            0      450     80.7    44.4    98.4    INC     38    61              
  UK14   MOX         10    149     62.5       587.5        10            18     12.5    50      87.1    75.3    94.1    CAR   40    60   27   67
  IVM    10          113   50      262.5      10           60            12.5   287.5   46.4    −12.5   83.3    CAR     0     100             

NL = no larvae were found in the coproculture. MOX = moxidectin injectable. IVM = ivermectin injectable.

###### 

The arithmetic mean (AM), minimum (MIN) and maximum (MAX) faecal egg counts before (pre) and after (post) treatment for each treatment group on the 8 farms (FR01-12) in France. The number of animals in each treatment group (n) and the number of animals with a positive faecal egg count after treatment (n pos) are provided, along with the % larvae before and after treatment (Oo = *Ostertagia ostertagi* and C = *Cooperia* spp). The percentage (%) efficacy calculated based on the arithmetic group mean is provided, along with the lower (L95) and upper (U95) 95% confidence limits. The anthelmintic resistance status (Status) is provided as EFF (efficacious), confirmed anthelmintic resistance (CAR) or Inconclusive (INC).

  Farm   Treatment   Pre   Post   Bootstrap   Larvae pre   Larvae post                                                                     
  ------ ----------- ----- ------ ----------- ------------ ------------- ---- ----- ------ ------- ------- ------- ----- ----- ----- ----- -----
  FR01   MOX         9     40     15          90           0             0    0     0      100     100.0   100.0   EFF   91    9     ND    
  IVM    9           57    15     165         0            0             0    0     100    100.0   100.0   EFF     ND                      
  FR04   MOX         7     41     15          75           2             9    0     45     77.5    37.5    100.0   INC   76    24    NL    
  IVM    9           38    15     75          4            12            0    45    68.3   35.0    95.0    INC                             
  FR05   MOX         8     168    15          465          0             0    0     0      100     100.0   100.0   EFF   0     100   ND    
  IVM    7           216   15     735         2            9             0    45    95.2   82.5    100.0   INC     ND                      
  FR06   MOX         9     110    15          315          6             47   0     135    52.6    −12.1   86.1    CAR   6     94    0     100
  IVM    9           138   15     600         3            37            0    210   68.5   2.5     98.1    INC     0     100               
  FR08   MOX         9     137    30          420          0             0    0     0      100     100.0   100.0   EFF   12    88    ND    
  IVM    9           170   30     465         0            0             0    0     100    100.0   100.0   EFF     ND                      
  FR09   MOX         10    74     15          165          6             21   0     45     70.1    43.9    87.7    CAR   NL    0     100   
  IVM    10          176   15     1125        1            2             0    15    98.8   94.3    100.0   EFF     6     94                
  FR11   MOX         9     75     15          210          2             5    0     30     92.7    78.9    100.0   INC   5     95    NL    
  IVM    8           84    15     240         0            0             0    0     100    100.0   100.0   EFF                             
  FR12   MOX         10    167    60          345          8             50   0     195    68.8    39.6    88.7    CAR   0     100   0     100
  IVM    10          161   75     345         5            36            0    120   77.3   57.6    94.1    CAR     0     100               

ND = for those groups with high efficacy no copro-culture was performed. NL = no larvae were found in coproculture. MOX = moxidectin injectable. IVM = ivermectin injectable.

###### 

The percentage efficacy calculated for *Cooperia* and *Ostertagia* separately for those treatment groups on those farms where larval identification was available before and after treatment (IVM = ivermectin; MOX = moxidectin). The number of groups with efficacy lower than 95% is provided (\<95%).

          *Cooperia* spp   *Ostertagia* spp          
  ------- ---------------- ------------------ ------ ------
  GE01    63%              61%                99%    98%
  GE02                                        95%    96%
  GE03                     69%                       100%
  GE04    100%             93%                100%   100%
  GE05    95%              98%                100%   100%
  GE06    95%              74%                99%    95%
  GE07    93%              90%                30%    85%
  GE08    −284%                               92%    
  GE09    92%                                 99%    
  GE10                     96%                       99%
  GE11    93%              84%                99%    92%
  GE12    36%              94%                71%    98%
  UK02    60%              86%                100%   83%
  UK07    98%              93%                100%   100%
  UK08    46%              83%                98%    98%
  UK10    99%              97%                100%   100%
  UK11    90%              98%                84%    96%
  UK12    73%              89%                95%    99%
  UK13    85%              96%                74%    97%
  UK14    12%              87%                100%   92%
  FR06    71%              55%                100%   100%
  FR12    66%              70%                100%   100%
  \<95%   14/19            13/19              5/20   5/20

[^1]: Contributed equally to the study and the manuscript.
